Skip to main content

Table 2 Model parameter values

From: Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

Parameter

Value

References

\(Ag_{0}\) (nmol)

14.95

Assuming 90% of 1 kg (1012) antigen-positie cells are in the distribution volume, \(V_{d}\)

\(V_{d}\) (L)

3.8

[13]

\(k_{ + }\) (M−1 h−1)

0.5

[13]

\(k_{ - }\) (h−1)

0.003

[13]

\(T_{c}\) (h)

40

[13]

\(T_{i}\) (h)

0.5

Estimated

\(T_{ci}\) (h)

100

Estimated

\(f_{L1} ,f_{S1}\)

0.18, 0.12

[13]

\(f_{L2} ,f_{S2}\)

0.08, 0.06

[13]

\(V_{RMECF} ,V_{d}\) (L)

0.22, 3.8

[13]

\(f_{Ac227}\)

0.007

Based on EOB fraction and assuming two 225Ac half-lives until time to injection

\(f_{Ab}\)

0.7

Estimated